Katryn N. Furuya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Katryn N. Furuya has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Ajay Kumar Jain
Department of Pediatrics Saint Louis University School of Medicine Saint Louis Missouri USA
1 shared publication - Alexandra Papadopoulou
Department of Gastroenterology, “Agia Sofia” Children’s Hospital, 11527 Athens, Greece
1 shared publication - Alexandre Rodrigues Ferreira
Universidade Federal de Minas Gerais, Brasil; Universidade Federal de Minas Gerais, Brasil
1 shared publication - Alisha M. Mavis
Atrium Health Charlotte North Carolina USA
1 shared publication Alisha S. Ching
Department of Pediatrics University of Wisconsin – Madison Madison Wisconsin USA
1 shared publication- Alison J. Gareau
Histocompatibility and Immunogenetics Laboratory, Alberta Public Laboratories, Calgary, Alberta, Canada
1 shared publication
Latest Publications
- Open Access
- 3 November 2026
- Published by Wiley in JPGN Reports
Disseminated histoplasmosis mimicking autoimmune hepatitis as a trigger of secondary hemophagocytic lymphohistiocytosis in a pediatric patient
Patients presenting with hemophagocytic lymphohistiocytosis (HLH) are often critically ill, and rapid identification of both HLH and underlying triggers in secondary HLH is essential for successful treatment. We present a case of secondary HLH activated by disseminated histoplasmosis (DH) that mimicked autoimmune hepatitis (AIH) on liver histology and briefly led to an incorrect liver diagnosis. Once DH was identified, he was treated with antifungals in addition to HLH therapies and stabilized. He was subsequently found to have a heterozygous variant of uncertain significance in STAT1 . Our case is the first in the literature to describe liver biopsies in a pediatric patient who has DH that had triggered HLH, and due to striking histology that mimicked AIH, important to report.
- 3 November 2026
- Published by Wiley in JPGN Reports
Open AccessDisseminated histoplasmosis mimicking autoimmune hepatitis as a trigger of secondary hemophagocytic lymphohistiocytosis in a pediatric patient
Patients presenting with hemophagocytic lymphohistiocytosis (HLH) are often critically ill, and rapid identification of both HLH and underlying triggers in secondary HLH is essential for successful treatment. We present a case of secondary HLH activated by disseminated histoplasmosis (DH) that mimicked autoimmune hepatitis (AIH) on liver histology and briefly led to an incorrect liver diagnosis. Once DH was identified, he was treated with antifungals in addition to HLH therapies and stabilized. He was subsequently found to have a heterozygous variant of uncertain significance in STAT1 . Our case is the first in the literature to describe liver biopsies in a pediatric patient who has DH that had triggered HLH, and due to striking histology that mimicked AIH, important to report.
- Open Access
- 8 September 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (9) , e70455
An Approach to Antibody‐Mediated Rejection in Pediatric Liver Transplantation
Antibody‐mediated rejection (AMR) is an important but infrequent cause of pediatric liver allograft injury. There is a lack of standardized guidance, and treatment approaches vary across institutions. A writing group from the Society of Pediatric Liver Transplantation conducted a comprehensive review of the published literature and collected institutional guidance documents from pediatric transplant centers across the United States to synthesize current diagnostic and management approaches to AMR in pediatric liver transplant recipients. AMR is diagnosed by the presence of characteristic histologic injury, C4d deposition, circulating donor‐specific antibody (DSA), and exclusion of alternative causes of graft dysfunction, including T cell–mediated rejection. Management strategies focus on reducing circulating DSA through therapeutic plasma exchange and suppressing ongoing immune activation with corticosteroids and intravenous immunoglobulin. In severe or refractory cases, targeted therapies such as rituximab, bortezomib, and eculizumab may be considered. A stepwise diagnostic and management algorithm is presented. This resource outlines a practical approach to the diagnosis and management of AMR in pediatric liver transplantation, serving as a reference for busy clinicians who may encounter this serious but underrecognized cause of graft dysfunction and loss.
- 8 September 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (9) , e70455
Open AccessAn Approach to Antibody‐Mediated Rejection in Pediatric Liver Transplantation
Antibody‐mediated rejection (AMR) is an important but infrequent cause of pediatric liver allograft injury. There is a lack of standardized guidance, and treatment approaches vary across institutions. A writing group from the Society of Pediatric Liver Transplantation conducted a comprehensive review of the published literature and collected institutional guidance documents from pediatric transplant centers across the United States to synthesize current diagnostic and management approaches to AMR in pediatric liver transplant recipients. AMR is diagnosed by the presence of characteristic histologic injury, C4d deposition, circulating donor‐specific antibody (DSA), and exclusion of alternative causes of graft dysfunction, including T cell–mediated rejection. Management strategies focus on reducing circulating DSA through therapeutic plasma exchange and suppressing ongoing immune activation with corticosteroids and intravenous immunoglobulin. In severe or refractory cases, targeted therapies such as rituximab, bortezomib, and eculizumab may be considered. A stepwise diagnostic and management algorithm is presented. This resource outlines a practical approach to the diagnosis and management of AMR in pediatric liver transplantation, serving as a reference for busy clinicians who may encounter this serious but underrecognized cause of graft dysfunction and loss.
- Open Access
- 26 June 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (10) , 101940
Longitudinal GGT Trajectories Identify Prognostic Phenotypes in Paediatric Primary Sclerosing Cholangitis
- 26 June 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (10) , 101940
Open AccessLongitudinal GGT Trajectories Identify Prognostic Phenotypes in Paediatric Primary Sclerosing Cholangitis
- Open Access
- 3 October 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (5) , 1098-1106
Cytomegalovirus prophylaxis in pediatric liver transplantation: A comparison of strategies across the Society of Pediatric Liver Transplantation (SPLIT) consortium
- 3 October 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (5) , 1098-1106
Open AccessCytomegalovirus prophylaxis in pediatric liver transplantation: A comparison of strategies across the Society of Pediatric Liver Transplantation (SPLIT) consortium
- Open Access
- 10 July 2023
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 191 (10) , 2578-2584
Turner syndrome may be associated with hepatic adenoma
Turner syndrome, caused by complete or partial loss of an X chromosome, is marked by a range of clinical manifestations including short stature, cardiovascular and renal disease. Hepatic involvement is an increasingly recognized concern. Steatosis and elevated transaminases are commonly observed in this population, but case reports have also described hepatic adenoma. Hepatic adenomas are rare, occurring in one per million people in the general population. They are typically benign but malignant transformation or rupture can occur. We sought to investigate whether Turner syndrome is associated with hepatic adenoma. Patients with Turner syndrome encountered at a single, academic institution between 2006 and 2020 were identified using ICD‐10 codes and demographic, medication, laboratory, and imaging data were analyzed. Of the 228 patients identified, 46.9% had liver function testing, which were abnormal in 48.6%. Five of 77 patients with hepatic imaging had abnormalities. Three patients (1.3%) had hepatic adenoma, one after presenting in hemorrhagic shock due to rupture. These findings suggest that patients with Turner syndrome may have an increased risk for developing hepatic adenoma. Annual monitoring of liver function tests is already recommended in Turner syndrome. The addition of periodic hepatic imaging may also be beneficial.
- 10 July 2023
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 191 (10) , 2578-2584
Open AccessTurner syndrome may be associated with hepatic adenoma
Turner syndrome, caused by complete or partial loss of an X chromosome, is marked by a range of clinical manifestations including short stature, cardiovascular and renal disease. Hepatic involvement is an increasingly recognized concern. Steatosis and elevated transaminases are commonly observed in this population, but case reports have also described hepatic adenoma. Hepatic adenomas are rare, occurring in one per million people in the general population. They are typically benign but malignant transformation or rupture can occur. We sought to investigate whether Turner syndrome is associated with hepatic adenoma. Patients with Turner syndrome encountered at a single, academic institution between 2006 and 2020 were identified using ICD‐10 codes and demographic, medication, laboratory, and imaging data were analyzed. Of the 228 patients identified, 46.9% had liver function testing, which were abnormal in 48.6%. Five of 77 patients with hepatic imaging had abnormalities. Three patients (1.3%) had hepatic adenoma, one after presenting in hemorrhagic shock due to rupture. These findings suggest that patients with Turner syndrome may have an increased risk for developing hepatic adenoma. Annual monitoring of liver function tests is already recommended in Turner syndrome. The addition of periodic hepatic imaging may also be beneficial.
- Open Access
- 1 March 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 76 (3) , 577-587
Sebelipase alfa in children and adults with lysosomal acid lipase deficiency: Final results of the ARISE study
- 1 March 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 76 (3) , 577-587
Open AccessSebelipase alfa in children and adults with lysosomal acid lipase deficiency: Final results of the ARISE study
- Open Access
- 1 January 2021
- Published by The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition in Pediatric Gastroenterology, Hepatology & Nutrition
- Vol. 24 (5) , 455-469
The PNPLA3 rs738409 Variant but not MBOAT7 rs641738 is a Risk Factor for Nonalcoholic Fatty Liver Disease in Obese U.S. Children of Hispanic Ethnicity
Mansoor S, et al. Pediatr Gastroenterol Hepatol Nutr. 2021 Sep;24(5):455-469. https://doi.org/10.5223/pghn.2021.24.5.455
- 1 January 2021
- Published by The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition in Pediatric Gastroenterology, Hepatology & Nutrition
- Vol. 24 (5) , 455-469
Open AccessThe PNPLA3 rs738409 Variant but not MBOAT7 rs641738 is a Risk Factor for Nonalcoholic Fatty Liver Disease in Obese U.S. Children of Hispanic Ethnicity
Mansoor S, et al. Pediatr Gastroenterol Hepatol Nutr. 2021 Sep;24(5):455-469. https://doi.org/10.5223/pghn.2021.24.5.455
- Open Access
- 16 September 2019
- Published by Wiley in Case Reports in Pediatrics
- Vol. 2019, 1-3
Mesenchymal Hamartoma in Children: A Diagnostic Challenge
Mesenchymal hamartoma is a benign tumor of the liver with a poorly understood pathogenesis. It is uncommon in older children, especially after 2 years of age. The signs and symptoms may be nonspecific; therefore, a high index of suspicion is required for diagnosis and treatment. We report a 5-year-old previously healthy male who presented with acute abdominal pain, fatigue, and fever. He was diagnosed with pneumonia initially and treated with antibiotics. A computed tomography (CT) scan done for evaluation of his persistent abdominal pain demonstrated a hepatic mass. Follow-up magnetic resonance imaging (MRI) of the liver demonstrated multiple serpiginous tubular-type structures, read as possible Caroli syndrome. He had a normal abdominal examination and normal biochemistries including alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, alkaline phosphatase, and alpha-fetoprotein. He was referred to our institution for second opinion. On further review of his imaging studies, the lesion was thought to be a mesenchymal hamartoma. He subsequently underwent resection of the mass. Pathology confirmed the diagnosis of mesenchymal hamartoma.
- 16 September 2019
- Published by Wiley in Case Reports in Pediatrics
- Vol. 2019, 1-3
Open AccessMesenchymal Hamartoma in Children: A Diagnostic Challenge
Mesenchymal hamartoma is a benign tumor of the liver with a poorly understood pathogenesis. It is uncommon in older children, especially after 2 years of age. The signs and symptoms may be nonspecific; therefore, a high index of suspicion is required for diagnosis and treatment. We report a 5-year-old previously healthy male who presented with acute abdominal pain, fatigue, and fever. He was diagnosed with pneumonia initially and treated with antibiotics. A computed tomography (CT) scan done for evaluation of his persistent abdominal pain demonstrated a hepatic mass. Follow-up magnetic resonance imaging (MRI) of the liver demonstrated multiple serpiginous tubular-type structures, read as possible Caroli syndrome. He had a normal abdominal examination and normal biochemistries including alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, alkaline phosphatase, and alpha-fetoprotein. He was referred to our institution for second opinion. On further review of his imaging studies, the lesion was thought to be a mesenchymal hamartoma. He subsequently underwent resection of the mass. Pathology confirmed the diagnosis of mesenchymal hamartoma.
- Open Access
- 24 April 2019
- Published by Wiley in Case Reports in Pediatrics
- Vol. 2019, 1-4
Diffuse Adenomatosis and Hepatocellular Carcinoma Treated with Liver Transplantation in an Adolescent Female with Kabuki Syndrome with a Novel KMT2D Gene Mutation
Kabuki syndrome (KS) is a rare disorder primarily associated with mutations in the KMT2D and KDM6A genes. Several tumors have been reported with KS; however, there have been no reports of hepatocellular carcinoma (HCC) or hepatic adenomatosis. We present an adolescent girl with KS and a novel KMT2D mutation who developed diffuse adenomatosis, HCC, and subsequently underwent liver transplantation.
- 24 April 2019
- Published by Wiley in Case Reports in Pediatrics
- Vol. 2019, 1-4
Open AccessDiffuse Adenomatosis and Hepatocellular Carcinoma Treated with Liver Transplantation in an Adolescent Female with Kabuki Syndrome with a Novel KMT2D Gene Mutation
Kabuki syndrome (KS) is a rare disorder primarily associated with mutations in the KMT2D and KDM6A genes. Several tumors have been reported with KS; however, there have been no reports of hepatocellular carcinoma (HCC) or hepatic adenomatosis. We present an adolescent girl with KS and a novel KMT2D mutation who developed diffuse adenomatosis, HCC, and subsequently underwent liver transplantation.
- Open Access
- 15 February 2018
- Published by Springer Nature
- p. 1-12
Pediatric Gastroenterologist and the Infant and Child Before Liver and Small Bowel Transplantation
- 15 February 2018
- Published by Springer Nature
- p. 1-12
Open AccessPediatric Gastroenterologist and the Infant and Child Before Liver and Small Bowel Transplantation